# Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors

> **NCT05410743** · PHASE1,PHASE2 · COMPLETED · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 30 (actual)

## Conditions studied

- SSTR2-positive Tumors

## Interventions

- **DRUG:** 177Lu-LNC1010 1
- **DRUG:** 177Lu-LNC1010 2
- **DRUG:** 177Lu-LNC1010 3
- **DRUG:** 177Lu-LNC1010 4

## Key facts

- **NCT ID:** NCT05410743
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2025-03-24
- **Final completion:** 2025-03-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05410743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05410743, "Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05410743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*